EE05302B1 - 4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks - Google Patents

4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks

Info

Publication number
EE05302B1
EE05302B1 EEP200300368A EEP200300368A EE05302B1 EE 05302 B1 EE05302 B1 EE 05302B1 EE P200300368 A EEP200300368 A EE P200300368A EE P200300368 A EEP200300368 A EE P200300368A EE 05302 B1 EE05302 B1 EE 05302B1
Authority
EE
Estonia
Prior art keywords
indan
fluoro
benzamide
medicament
manufacture
Prior art date
Application number
EEP200300368A
Other languages
English (en)
Estonian (et)
Inventor
Wohlfart Paulus
Suzuki Teri
M. Dharanipragada Ramalinga
Safarova Alena
Walser Armin
Strobel Hartmut
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200300368A publication Critical patent/EE200300368A/xx
Publication of EE05302B1 publication Critical patent/EE05302B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300368A 2001-02-13 2002-02-12 4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks EE05302B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01102852 2001-02-13
PCT/EP2002/001443 WO2002064146A1 (en) 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Publications (2)

Publication Number Publication Date
EE200300368A EE200300368A (et) 2003-10-15
EE05302B1 true EE05302B1 (et) 2010-06-15

Family

ID=8176423

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300368A EE05302B1 (et) 2001-02-13 2002-02-12 4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks

Country Status (34)

Country Link
US (3) US6617359B2 (no)
EP (1) EP1361882B1 (no)
JP (1) JP4317689B2 (no)
KR (1) KR101017531B1 (no)
CN (1) CN100553631C (no)
AT (1) ATE344669T1 (no)
AU (1) AU2002253009B2 (no)
BG (1) BG66065B1 (no)
BR (1) BR0207178A (no)
CA (1) CA2437966C (no)
CY (1) CY1106278T1 (no)
CZ (1) CZ20032154A3 (no)
DE (1) DE60215919T2 (no)
DK (1) DK1361882T3 (no)
EE (1) EE05302B1 (no)
ES (1) ES2274025T3 (no)
HK (1) HK1062140A1 (no)
HR (1) HRP20030646A2 (no)
HU (1) HUP0302845A3 (no)
IL (2) IL157208A0 (no)
MX (1) MXPA03006841A (no)
MY (1) MY135778A (no)
NO (1) NO333522B1 (no)
NZ (1) NZ527469A (no)
PE (1) PE20020884A1 (no)
PL (1) PL363452A1 (no)
PT (1) PT1361882E (no)
RS (1) RS51645B (no)
RU (1) RU2308946C2 (no)
SI (1) SI1361882T1 (no)
SK (1) SK286513B6 (no)
TW (1) TWI241190B (no)
WO (1) WO2002064146A1 (no)
ZA (1) ZA200305412B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
MY136316A (en) * 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AU2003279996B2 (en) 2002-10-21 2009-07-09 Janssen Pharmaceutica, N.V. Substituted tetralins and indanes and their use
AU2003294441A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
ES2298819T3 (es) * 2003-07-03 2008-05-16 Eli Lilly And Company Derivados de indano como agonistas de receptor muscarinico.
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
PT1708690T (pt) 2003-11-17 2016-09-19 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
EP2436379A1 (en) * 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
WO2006055833A2 (en) * 2004-11-19 2006-05-26 Children's Hospital Medical Center Gtpase inhibitors and use thereof for controlling platelet hyperactivity
US20060185492A1 (en) 2005-02-18 2006-08-24 Francois Chianese Shoulder bushing for saw blades
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US7795101B2 (en) * 2006-04-03 2010-09-14 United Microelectronics Corp. Method of forming a MOS transistor
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
KR101349187B1 (ko) * 2006-12-05 2014-01-10 (주)아모레퍼시픽 지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
JP2011500577A (ja) * 2007-10-09 2011-01-06 ノバルティス アーゲー バルサルタンの医薬製剤
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
AU2011326241B2 (en) 2010-11-09 2016-11-17 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EA031746B1 (ru) 2013-03-15 2019-02-28 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
WO2015089182A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
MX2017003516A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc).
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3481820B1 (en) 2016-07-07 2023-10-18 Cyclerion Therapeutics, Inc. Solid forms of an sgc stimulator
MA45592A (fr) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc Promédicaments à base de phosphore de stimulateurs de sgc

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) * 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
CA2410597A1 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7105513B2 (en) 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
NO20033546D0 (no) 2003-08-11
NO20033546L (no) 2003-09-24
EP1361882A1 (en) 2003-11-19
PL363452A1 (en) 2004-11-15
BR0207178A (pt) 2004-03-30
US7202278B2 (en) 2007-04-10
US20030022939A1 (en) 2003-01-30
BG107994A (bg) 2004-08-31
MY135778A (en) 2008-06-30
PE20020884A1 (es) 2002-11-25
RS61703A (en) 2006-12-15
PT1361882E (pt) 2007-01-31
US20050054729A1 (en) 2005-03-10
ZA200305412B (en) 2004-09-02
TWI241190B (en) 2005-10-11
NO333522B1 (no) 2013-07-01
DE60215919D1 (de) 2006-12-21
KR20030074809A (ko) 2003-09-19
US6617359B2 (en) 2003-09-09
DK1361882T3 (da) 2007-03-12
RS51645B (en) 2011-10-31
WO2002064146A1 (en) 2002-08-22
AU2002253009B2 (en) 2006-09-14
SK286513B6 (sk) 2008-12-05
EP1361882B1 (en) 2006-11-08
EE200300368A (et) 2003-10-15
CA2437966C (en) 2011-06-14
CY1106278T1 (el) 2011-10-12
RU2003127750A (ru) 2005-03-10
DE60215919T2 (de) 2007-05-31
HUP0302845A3 (en) 2005-11-28
HK1062140A1 (en) 2004-10-21
HRP20030646A2 (en) 2005-06-30
IL157208A0 (en) 2004-02-19
IL157208A (en) 2009-09-22
ATE344669T1 (de) 2006-11-15
KR101017531B1 (ko) 2011-02-28
CN100553631C (zh) 2009-10-28
HUP0302845A2 (hu) 2003-12-29
RU2308946C2 (ru) 2007-10-27
ES2274025T3 (es) 2007-05-16
CN1496264A (zh) 2004-05-12
JP4317689B2 (ja) 2009-08-19
SK10112003A3 (sk) 2004-01-08
CA2437966A1 (en) 2002-08-22
CZ20032154A3 (cs) 2004-05-12
SI1361882T1 (sl) 2007-02-28
JP2004518713A (ja) 2004-06-24
MXPA03006841A (es) 2003-11-13
US20040019114A1 (en) 2004-01-29
US6812253B2 (en) 2004-11-02
BG66065B1 (bg) 2011-01-31
NZ527469A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
EE05302B1 (et) 4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
SE0200979D0 (sv) New compounds
SE0100569D0 (sv) New compounds
SE0101387D0 (sv) Novel compounds
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
SE0301882D0 (sv) New use I
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
SE0301886D0 (sv) New use V
UY27368A1 (es) Nuevos compuestos
BR0309185A (pt) Medicamento contendo beta-miméticos e um novo anticolinérgico
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
DK1030667T3 (da) Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
HRP20120344T1 (hr) N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije
SE0004101D0 (sv) New use
NO20033413D0 (no) Krystallmodifisering av et syklisk depsipeptid med forbedret aktivitet
UY28129A1 (es) Complejos de e.-2-metoxi.-n-(3-(4-(3-metil-4-(6-metil piridin-3- iloxi)fenilamino)quinazolin-6-il)alil)acetamida, su procedimiento de producción y uso
SE0000303D0 (sv) Novel compounds
SE0004462D0 (sv) Novel method and use
ATE446759T1 (de) Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
DE60228687D1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130212